Sistemic Launches New Range of Drug Discovery Research SistemRNATM (v2) Profiles

Sistemic Launches New Range of Drug Discovery Research SistemRNATM (v2) Profiles
Novel microRNA-based "compound positioning/characterization" platform expands into Oncology and Inflammation

GLASGOW, Scotland--(BUSINESS WIRE)--Sistemic today announced immediate availability new SistemRNATM product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets. This announcement comes following their recent news of expansion into the US market with headquarters located in Boston.

"The validity of our use of microRNA profiling as a sentinel marker of phenotypic effects in model systems is overwhelming, and we are seeing time and time again very strong correlations between microRNA changes and drug effects"
.Instead of the traditional target-orientated approach, SistemRNATM Technology uses a compound-centric approach. This involves identifying drug effects by associative changes in microRNA expression profiles and their analysis in context against a growing proprietary database of known drug responses. Client compounds can then be characterized on the basis of indication, mechanism of action and adverse effects. "The validity of our use of microRNA profiling as a sentinel marker of phenotypic effects in model systems is overwhelming, and we are seeing time and time again very strong correlations between microRNA changes and drug effects" stated Dr Vincent O'Brien, CSO.

The new oncology and inflammation products will be of value to pharmaceutical and biotechnology companies that are seeking to position new compounds or reposition existing compounds in these therapeutic areas. Launched in response to customer demand, the oncology platform knowledgebase contains eight major drug classes, including HDACi, with five or more representatives from each class. Prof. Chris Hillier, CEO of Sistemic commented "The strength of Sistemic's approach is that we provide an extremely reliable way to make key decisions on safety and efficacy based on very strong biological information about the properties of your compound without reference to the expected target. This lack of bias produces valuable evidence to support drug development and has the power to create some very exciting opportunities."

More information about Sistemic is available at http://www.sistemic.co.uk

Contacts
Sistemic
Prof. Chris Hillier, CEO
Phone: +44 (0) 7908 154979
Email: [email protected]
or
Dr. Verna McErlane, Director of Commercial Operations, International
Phone: +44 (0) 7855 376358
Email: [email protected]

Permalink: http://www.businesswire.com/news/home/20100503005128/en/Sistemic-Launches-Range-Drug-Discovery-Research-SistemRNATM

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.